Loading organizations...
Based in Houston, Texas, Diakonos Oncology is a clinical-stage biotechnology company developing patient-derived dendritic cell vaccines for aggressive cancers like glioblastoma and pancreatic ductal adenocarcinoma. The company's lead immunotherapy candidate, DOC1021, recently received Fast Track designation from the FDA after a Phase 1 clinical trial demonstrated that 93 percent of 15 treated glioblastoma patients survived beyond twelve months. To finance its ongoing clinical development and upcoming Phase 2 trials, the enterprise has secured a total of $31.4 million in private equity and venture capital funding. This capitalization includes a recent $20 million financing round led by the Baylor College of Medicine Brain Tumor Investment Fund, alongside previous backing from RESTEM. Utilizing institutional research originating from the Baylor College of Medicine, Diakonos Oncology was founded in 2016 by Mike Wicks, Jay Hartenbach, Dan Faust, and Will Decker.
Diakonos Oncology has raised $31.4M across 2 funding rounds.
Diakonos Oncology has raised $31.4M in total across 2 funding rounds.
Diakonos Oncology has raised $31.4M across 2 funding rounds. Most recently, it raised $20.0M Other Equity in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $20M Venture Round | — | Mike Wicks, Joseph Petrosino, John Higgins, Buttonwood Group Advisors | Announced |
| Aug 26, 2024 | $11.4M Seed | Andrés Isaias | — | Announced |
Diakonos Oncology has raised $31.4M in total across 2 funding rounds.
Diakonos Oncology's investors include Mike Wicks, Joseph Petrosino, John Higgins, Buttonwood Group Advisors, Andrés Isaias.
